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Jembrana disease virus (JDV) is a newly identified bovine lentivirus that is closely related to the bovine
immunodeficiency virus (BIV). JDV contains a tat gene, encoded by two exons, which has potent transactivation
activity. Cotransfection of the JDV tat expression plasmid with the JDV promoter chloramphenicol acetyltransferase (CAT) construct pJDV-U3R resulted in a substantial increase in the level of CAT mRNA transcribed from the JDV long terminal repeat (LTR) and a dramatic increase in the CAT protein level. Deletion
analysis of the LTR sequences showed that sequences spanning nucleotides 268 to 153, including the TATA
box and the predicted first stem-loop structure of the predicted Tat response element (TAR), were required for
efficient transactivation. The results, derived from site-directed mutagenesis experiments, suggested that the
base pairing in the stem of the first stem-loop structure in the TAR region was important for JDV Tat-mediated
transactivation; in contrast, nucleotide substitutions in the loop region of JDV TAR had less effect. For the JDV
LTR, upstream sequences, from nucleotide 2196 and beyond, as well as the predicted secondary structures in
the R region, may have a negative effect on basal JDV promoter activity. Deletion of these regions resulted in
a four- to fivefold increase in basal expression. The JDV Tat is also a potent transactivator of other animal and
primate lentivirus promoters. It transactivated BIV and human immunodeficiency virus type 1 (HIV-1) LTRs
to levels similar to those with their homologous Tat proteins. In contrast, HIV-1 Tat has minimal effects on JDV
LTR expression, whereas BIV Tat moderately transactivated the JDV LTR. Our study suggests that JDV may
use a mechanism of transactivation similar but not identical to those of other animal and primate lentiviruses.
flanking long terminal repeats (LTRs) and the structural genes
gag, pol, and env, which are characteristics of all retroviruses.
On the basis of sequence analysis, a number of accessory genes
represented by small open reading frames (ORFs) exist in the
central and 39-terminal regions of the JDV genome. In particular, the homologous sequence for the regulatory gene tat,
which codes for the important trans-acting regulatory protein
found in all lentiviruses characterized to date, was identified
(9).
The putative Tat protein of JDV was predicted to be expressed from a multiply spliced transcript that includes two
coding exons derived from separate ORFs in the central and
39-terminal regions of the genome (9). In the first coding exon
there was a cysteine-rich region, a core region, and a downstream basic domain that was found in the Tat proteins of most
lentiviruses, including BIV 127 (19). These domains have been
suggested to be important for their nucleic acid-binding and
transactivation properties (8, 24). The presence of a BIV homologous tat sequence and the presence of a Tat response
element (TAR)-like element in the extreme 59 end of the JDV
RNA strongly suggest that viral transactivation may occur and
that it is mediated through an RNA stem-loop structure similar
to those found in BIV, equine infectious anemia virus (EIAV),
and primate lentiviruses (7, 8, 24).
To study the regulation of JDV gene expression, whether
there is a functional Tat protein, and whether active JDV
transcription and transactivation are responsible for high-titer
JDV expression in infected animals, we characterized the JDV
promoter and its ability to be transactivated by its homologous
and heterologous Tat proteins. The JDV tat exon 1 coding
region, based on sequence analysis, was cloned into a eukaryotic expression vector that contains the Rous sarcoma virus

Jembrana disease was first recognized in 1964 as an acute
and infectious disease affecting Bali cattle in the Jembrana
district of Bali in Indonesia (5, 40). The virus that causes the
disease was recently characterized (9, 10). The morphogenesis,
protein structure, antigenic reactivity, and sequence analysis
suggested that this virus is a lentivirus related to the bovine
immunodeficiency virus (BIV) (9, 10, 40). The most noticeable
difference between Jembrana disease virus (JDV) and BIV is
the disease induced by each virus in cattle. JDV causes an
acute disease in Bali cattle (Bos javanicus) and is endemic in
parts of Indonesia (5, 40). In experimentally inoculated cattle,
the incubation period varied from 4.5 to 12 days before the
onset of clinical symptoms, which included fever, lethargy,
anorexia, and lymphadenopathy; the mortality rate was about
17%. In recovered animals there was no recurrence of disease
(35, 40). In contrast, experimental BIV infection results in only
a subclinical disease syndrome, with transient lymphocytosis
and possibly lymphadenopathy associated with follicular hyperplasia, and with no obvious clinical disease (6, 36). Another
difference between BIV and JDV is the high titer of JDV (108
50% cattle infective doses per ml) in plasma during the febrile
period of the disease; this has not been observed for BIV (6,
35, 36, 40).
JDV is closely related to BIV on the basis of nucleotide
sequence analysis. The complete RNA genome of JDV is 7,732
bp (9). It is 750 bp shorter than the genome of BIV 127 (19).
Like BIV and other lentiviruses, the JDV genome contains
* Corresponding author. Mailing address: School of Biological Sciences, University of Nebraska, E249 Beadle Center, P.O. Box 880666,
Lincoln, NE 68588-0666. Phone: (402) 472-4550. Fax: (402) 472-8722.
E-mail: cwood1@unl.edu.
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FIG. 1. Schematic representation of the JDV LTR promoter construct and the various derived deletion clones used for transient transfection analysis. The locations
of the various promoter elements, U3, R, U5, the TATA box, and the putative TAR region, are indicated. Several predicted regulatory factor binding sites, for NF-kB,
SP-1, AP-4, and the core enhancer element, are also shown. Solid lines represent the sequences retained in the LTR deletion plasmids. The 59 and 39 ends for each
deletion plasmid are numbered with respect to the transcription start site (11).

(RSV) promoter. The promoter activities of the intact JDV
promoter, a series of 59 and 39 JDV LTR deletion mutants, and
several site-directed mutants were then studied. Our studies
showed that JDV Tat encoded by exon 1 possessed strong
transactivation activities and that the predicted JDV TAR region was important for the transactivation. The JDV Tat is a
ubiquitous and potent transactivator that activated other lentivirus promoters tested in a variety of cell types.
MATERIALS AND METHODS
Cell culture. The CV-1 cell line (ATCC CCL70) and primary fetal bovine lung
(FBL) cells (36) were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin.
All FBL cells used for transient transfection were cultured in vitro for no more
than six passages.
Construction of plasmids. The various plasmids that were used in the study,
pBIV-CAT, pBTATC, pHIV-CAT, pRSV-HTAT, pRSV-CAT, pHTLV-CAT,
pSIV-CAT, and pHIV-2-CAT, have been described previously (25, 27).
To generate the Tat eukaryotic expression plasmid, the putative JDV tat exon
1 coding sequences were PCR amplified from JDV clone 147 (nucleotides [nt]
5000 to 7732) (9). By using the forward primer 59 CAG ATA TGC CTG GTC
CCT GG 39 and the reverse primer 59 TCC AGG ATC CAA CGA TCT AGT
39, the 321-bp fragment from nt 5005 to nt 5326 was amplified. The PCR product
was then cloned into the pGEM-T vector (Promega). To generate the Tat
expression clone, the tat insert was released from the pGEM-T vector by digestion with NcoI, blunt ended by treatment with Klenow fragment, and then cut
with BamHI. The vector plasmid pRSV-CAT (25) was cut with HindIII and filled
in with Klenow fragment, followed by digestion with BamHI to release the
chloramphenicol acetyltransferase (CAT) gene. The tat fragment was then ligated to the vector downstream of the RSV LTR promoter. This JDV tat
expression plasmid was designated pRSV-JTAT.
To construct the JDV LTR clone from JDV clone 147, an EcoRI fragment (nt
6798 to 7732) which contained the U3 and R regions was subcloned into vector
pUC18 to generate plasmid pUC18-U3R. To generate a clone with the entire
LTR segment, pUC18-U3R and another JDV plasmid, 139, which contained a
JDV gene fragment from nt 19 to nt 2881, were used as templates for overlapping
PCR. The primers used were pUC18 primer 40 (59 GTT TTC CCA GTC ACG
AC 39), which is upstream of the U3 region, and JDV primer U5 (59 GCG CAA
GCT TTT GGG TGG TTC T 39, mutated at nt 159 to engineer a HindIII site),
which ends at the boundary of JDV U5 and the noncoding region of the gag gene.
Because the two template plasmids overlapped by 110 bp at the R region, the
PCR product covered the entire JDV LTR. The PCR product was then inserted
into vector pGEM-T to generate plasmid pGEM-JLTR. The JDV LTR fragment
was released from pGEM-JLTR by cutting with HindIII and was then ligated

into pUC18-CAT at the HindIII site to generate plasmid pJLTR-CAT. This JDV
LTR clone was confirmed by DNA sequencing.
To construct various LTR 39-end deletion clones, PCR was performed with a
single forward upstream primer, JDV-U3.1 (nt 7324 to 7347; 59 GTC CTC CTA
GTT CGG ATC CTT T 39, mutated to generate a BamHI site) and various LTR
downstream deletion primers: JDV-R (nt 7732 to 7713; 59 TGC CGA AAG CCA
AAC GAC CT 39), JDV-R2 (nt 7709 to 7690; 59 TTC ACC TCG GCC GGG
CTA CC 39), JDV-R3 (nt 7677 to 7658; 59 TGC CTT ACA GGG TAC CAG CT
39, mutated to generate a KpnI site), and JDV-R4 (nt 7651 to 7628; 59 TCG AAG
CTT CAG CTA TCC AGA GC 39, mutated to generate a HindIII site). The
PCR products were then cloned into the pGEM-T vector before insertion into a
CAT expression vector. These 39 deletion clones were designated pJDV-U3R,
p3D185, p3D153, and p3D121, according to their positions in the LTR (Fig.
1).
To construct 59 deletion clones, similar strategies were used, and the 59 deletion fragments were PCR amplified by using plasmid pJD1108 as a template. A
single downstream reverse primer, CAT-R1 (59 GTC TTT CAT TGC CAT ACG
GA 39), located in the CAT gene, and various upstream forward primers, U3-2
(nt 7431 to 7450; 59 CCC GGA GCT CGA AAT ATC TGA 39), U3-3 (nt 7543
to 7562; 59 CAC GTA GCT TGG AGG ATC AG 39), U3-4 (nt 7554 to 7573; 59
GAG GAT CCG CTG ATA CCT AA 39), and U3-5 (nt 7575 to 7598; 59 AAT
AGT AGT TCC CTT TTG CAT GCT 39) were used for PCR. All the amplified
fragments were cut with EcoRI at a site located within the reverse primer
CAT-R1 and then ligated into vector pJLTR-CAT, which was cut with HindIII,
blunt ended, and then cut with EcoRI. These 59 deletion clones were designated
p5D-196, p5D-81, p5D-68, and p5D-50. Likewise, two internal deletion clones,
designated pJD-81153 and pJD-68153, were constructed by using plasmid
p3D153 as a template for PCR (Fig. 1).
Site-directed mutagenesis. All mutants were generated by overlapping PCR
methodology as described elsewhere (1). PCR products were cloned into vector
pGCAT-A upstream of the CAT gene. The primers used in the mutagenesis
studies are listed below (Table 1).
Northern blotting. Northern blotting was carried out as described previously
(1, 42). Briefly, RNA samples were purified with the RNeasy Mini kit (Qiagen,
Hilden, Germany), and 10 mg of each RNA sample was separated in a 1.2%
formaldehyde agarose gel and then transferred to a supported nitrocellulose
membrane. The membrane was baked at 80°C for 2 h, prehybridized (25 mM
KPO4 [pH 7.4], 53 SSC [13 SSC is 0.15 M NaCl plus 0.015 M sodium citrate],
53 Denhardt’s solution, 50 mg of salmon sperm DNA/ml, 50% formamide) for
2 to 5 h, then hybridized with a 32P-labeled DNA probe in hybridization solution
(prehybridization solution containing 10% dextran sulfate). After hybridization,
the membrane was washed twice, each time with 23 SSC–0.1% sodium dodecyl
sulfate (SDS) and 0.253 SSC–0.1% SDS solutions at 65°C, and then exposed to
Kodak XAR-5 film with an intensifying screen at 280°C overnight. The probes
used were labeled by the random-primed labeling method with the NEBlot kit
(New England Biolabs). The CAT DNA fragment used for a probe was cut out
from plasmid pGCAT-A (Promega), and the glyceraldehyde-3-phosphate dehy-
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TABLE 1. Oligonucleotide primers used for site-directed mutagenesis in the JDV TAR region
Sequencea

Oligonucleotide
d

JMR1
JMR2
JMR3
JMR4
JMR5
JMR6
JMR7
JMR8

Positionsb

59CAACGGGTACCTGGATAGCTGACAGCTC39
59CTATCCAGGTACCCGTTGCAGAATGCTC39
59CTCTGATCAGCTGACAGCTCCGAGCC39
59AGCTGATCAGAGCCCCGTTGCAGAATG39
59CTCTGGATAGCGCTCAGCTCCGAGCC39
59CTCGGAGCTGAGCGCTATCCAGAGCC39
59GCTGACTAGTCCGAGCCCCAGCTGGTA39
59GCTCGGACTAGTCAGCTATCCAGA39

24 to 124
114 to 214
15 to 130
116 to 211
15 to 130
128 to 13
114 to 141
129 to 16

Polarityc

1
2
1
2
1
2
1
2

a

Mutated nucleotides are underlined.
The transcription start site is referred to as 11.
1, sense orientation; 2, antisense orientation.
d
JMR1 and JMR2 were used to generate mutant pJD153M; JMR3 and JMR4 were used to generate mutant pJD153M2; JMR5 and JMR6 were used to generate
mutant pJD153M3; JMR7 and JMR8 were used to generate mutant pJD153M4 (see Fig. 4B).
b
c

drogenase (GAPDH) gene probe was used as an internal control. The GAPDH
DNA fragment was amplified by PCR with primers GAPDH1 (59 CCA TGG
AGA AGG CTG GG 39) and GAPDH2 (59 CAA AGT TGT CAT GGA TGA
CC 39).
Transfection and CAT assay. Transfection was carried out with CV-1 and FBL
cells. About 2 3 105 cells were plated into each 60-mm plate with 5 ml of DMEM
containing penicillin-streptomycin and 10% FBS. About 24 h after plating, the
cells were transfected with plasmid DNA with Lipofectamine (GIBCO-BRL).
Depending on the experiments, 0.25 to 1 mg of CAT reporter plasmid DNA, with
various amounts (0 to 2.5 mg) of tat plasmid DNA, was mixed with 10 ml of
Lipofectamine reagent in 500 ml of DMEM. The DNA mixture was then added
to the cells, which had been washed twice with DMEM without FBS. Fresh
DMEM with 20% FBS was added to the transfected cells 12 h after transfection.
At 48 h after transfection, cells were lysed in 1 ml of lysis buffer (CAT ELISA kit;
Boehringer Mannheim).
The protein concentration of each lysate was determined by the bicinchoninic
acid protein assay (Pierce), and the amount of CAT enzyme in 10 mg of total
cellular protein was determined by the CAT enzyme-linked immunosorbent
assay (ELISA) using protocols described by the manufacturer (Boehringer
Mannheim). In some cases, the b-galactosidase (b-Gal) expression plasmid was
cotransfected into cells to normalize the transfection efficiency. The relative
amounts of CAT were first determined by the CAT ELISA and then standardized to the experimental b-Gal units. The b-Gal activities were determined by a
standard assay as described in the molecular cloning manual of Sambrook et al.
(33). Each transfection was repeated three times, and the data were averaged.
Sequence analysis. The secondary structure of RNA was determined by using
the RNA folding program of the Genetics Computer Group (GCG) (Wisconsin
package). Protein sequences were aligned with the GCG Pileup program. The tat
sequences from the JDV genome (GenBank accession no. U21603), BIV genome (GenBank accession no. M32690), and human immunodeficiency virus
type 1 (HIV-1) genome (GenBank locus, hivhxb2cg) were translated into amino
acid sequences with the GCG Translate program. The HIV-2 Tat peptide sequence (GenBank accession no. p04605) was obtained from SwissProt.

To further verify that JDV Tat encoded by exon 1 is a potent
transactivator which acts on the JDV LTR at the transcriptional level, Northern blot analysis experiments were performed. When 1 mg of pJDV-U3R was cotransfected into
CV-1 cells with different concentrations of the JDV tat plasmid, higher levels of CAT mRNA were detected in the presence of tat (Fig. 3). This is consistent with the increase in CAT
protein levels in the presence of the JDV tat (Fig. 2). It remains
to be determined whether the observed transactivation reflects
direct interaction of the putative JDV Tat with the LTR or
whether it is indirectly mediated by Tat through cellular factors.
Localization of regulatory elements important for basal and
transactivation activity in JDV LTR by deletion analysis. Sequence analysis showed that the U3 region of the JDV LTR
contained many cis-regulatory factor binding sites, such as
those for NF-kB, SP-1, and AP-4 (Fig. 1) (9). The R region of
JDV was predicted to contain the putative TAR region, corresponding to the TAR of BIV (19–21), and the JDV R region
can potentially form three stem-loop secondary structures similar to those of BIV (Fig. 4A) (9). To define the cis- and
trans-acting sequences in the LTR necessary for basal expression as well as the TARs on the JDV LTR, we constructed a

RESULTS
JDV Tat encoded by exon 1 can activate LTR to high levels.
To test the ability of JDV Tat to transactivate the JDV LTR,
the reporter plasmid pJDV-U3R was transfected into CV-1
and FBL cells with or without plasmid pRSV-JTAT, and the
expression of the LTR was then determined by CAT analysis.
The basal expression levels of the JDV LTR were higher in
FBL cells than in CV-1 cells (data not shown). In CV-1 cells,
when 1 mg of pJDV-U3R was cotransfected with different
amounts of pRSV-JTAT (0, 0.25, 0.5, 1.0, and 2.5 mg), JDV
Tat was found to transactivate LTR expression 27-fold with the
addition of 1 mg of plasmid pRSV-JTAT (Fig. 2). However,
high concentrations of the tat plasmid suppressed transactivation. In FBL cells, the highest transactivation level (10-fold)
was achieved when 0.5 mg of the tat plasmid was added (Fig. 2).
Even though overall CAT activity in the presence of Tat was
much higher in FBL cells than in CV-1 cells, the relative
activation by Tat was still much lower in FBL cells. The lower
transactivation was likely due to the high basal expression
levels of the JDV LTR in FBL cells.

FIG. 2. Cotransfection of the JDV LTR with various amounts of JDV tat
(pRSV-JTAT). pJDV-U3R was transfected into either FBL (0.5 mg of DNA) or
CV-1 (1 mg of DNA) cells with varying amounts of pRSV-JTAT (0, 0.25, 0.5, 1.0,
and 2.5 mg of DNA) by using Lipofectamine. The total amount of DNA used was
kept constant by adjusting with pUC18 DNA. The fold activation, calculated as
the average concentration of CAT protein (picograms of CAT protein per
milligram of total cellular protein) in the presence of tat divided by the average
concentration of CAT protein in the absence of tat, is shown above each bar.
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FIG. 3. Northern blot analysis for CAT-specific transcripts. The analysis was
carried out with a 32P-labeled CAT-specific probe. The two CAT-specific RNA
species indicated by arrows are the spliced and unspliced forms of the CAT
mRNA (2). A GAPDH probe was used as an internal control to normalize the
amount of RNA loaded onto each lane.

series of 59 deletion mutants in which we deleted one or more
of the regulatory elements NF-kB, SP-1, core enhancer, and
AP-4 (clones p5D-196, p5D-81, p5D-68, and p5D-50 [Fig. 1]).
To map the potential TAR sites on the LTR, a set of 39
deletion mutants was also generated. These mutants were designed in such a way as to delete the U5 region alone or the U5
region as well as one or more of the three predicted stem-loop
structures in the putative TAR region in the LTR (clones
pJDV-U3R, p3D185, p3D153, and p3D121 [Fig. 1]). Two
other internal deletion mutants, pJD-81153 and pJD-68153,
were constructed to further narrow down the region in the
JDV LTR that was required for the promoter activity and
transactivation function. Transfection of these LTR deletion
plasmids in the absence or presence of JDV tat (pRSV-JTAT)
was performed in order to determine the effects of each of the
predicted elements in viral transcription and transactivation.
Like the wild-type JDV LTR, most LTR deletion mutants
had higher basal activities in FBL cells than in CV-1 cells
(Table 2). The JDV LTR construct, pJDV-LTR, which contained the entire U3, R, and U5 regions of the LTR, had
activity similar to that of the promoter construct, pJDV-U3R,
which contained only the U3 and R regions. This suggested
that the U5 region does not play an important role in basal
promoter functions, as seen in other retroviruses (7). It was
interesting that the basal promoter activity of pJD-196, which
had a 59 deletion including the NF-kB site, was much higher
than that of the intact LTR. Its activity was about fivefold
higher in CV-1 cells and fourfold higher in FBL cells. It is
possible that a JDV negative regulatory element is located
between nt 2236 and 2196, as was found previously in a
number of other lentivirus LTRs, including those of BIV, HIV,
and EIAV (7, 15, 31). Deletion of sequences between nt 2196
and 250, represented by clones p5D-81, p5D-68, and p5D-50,
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reduced the promoter activity relative to clone p5D-196 in
both FBL and CV-1 cells. Clone p5D-50, in which all regulatory elements except the TATA box were deleted, had the
lowest basal activity. The predicted regulatory elements, such
as NF-kB, SP-1, core enhancer, and AP-4, may therefore play
an important positive role in the basal expression of the JDV
LTR. Deletion of the LTR from the 39 end was not expected to
affect basal promoter activity. The deletion of the U5 in pJDVU3R had no effect, and deletion of part of the R region up to
position 153 in p3D153 also had little effect. Interestingly,
deletion of part of the R region, including the predicted TAR
stem-loops, in clone p3D121, resulted in much-elevated basal
expression levels both in CV-1 and in FBL cells (Table 2),
suggesting that the presence of the secondary structure in the
R region or other factors targeting the R region may be involved in affecting basal expression of the LTR. Two other
deletion clones, pJD-81153 and pJD-68153, which retained
all the 59 (SP1, AP-1, and TATA) and 39 elements essential for
basal promoter activity, have activities slightly lower than, but
not significantly different from, that of the intact promoter
(Table 2).
In the presence of JDV Tat, all the LTR 59 deletion clones
except p5D-50 were transactivated about 15- to 32-fold in
CV-1 cells and about 5- to 10-fold in FBL cells (Table 2).
Although basal promoter activity was retained in the deletion
construct p5D-50, it was not transactivated by JDV Tat. This
suggests that the upstream elements in the U3 region, such as
AP-4, may be required for effective transactivation by Tat.
Among the three active 59 deletion clones (p5D-196, p5D-81,
and p5D-68), p5D-196 was least responsive to Tat transactivation; the lower level of transactivation observed in pJD-196
could be due to the increased basal expression level. In the 39
deletion mutants, deletion of U5 in pJDV-U3R and deletion of
the third and of both the second and the third stem-loop of the
TAR region in p3D185 and p3D153, respectively, seemed to
have no marked effect on transactivation. Therefore, the second and third stem-loops of the TAR structure located in the
R region of the LTR seem to be dispensable for transactivation
by Tat. The most significant change in Tat transactivation was
observed in pJD121. This clone had lost its ability to be stimulated by Tat in both CV-1 and FBL cells (Table 2). This
suggests that the putative stem-loop 1 of the TAR region
formed by nt 1 to 30 was critical for Tat transactivation. It was
also of interest that the transactivation by Tat in FBL cells, for
most of the promoter constructs tested, seemed to be much
lower than that induced in CV-1 cells. This was most likely due
to the much higher basal expression levels of the promoter
constructs in FBL cells. Despite these differences, the transactivation patterns of these promoters in the two different cell
types were very similar.
The stem-loop structure is required for transactivation by
JDV Tat. The deletion analysis described above suggests that
JDV Tat can strongly activate the JDV LTR through binding
to the TAR region located downstream of the transcription
start site. The TAR RNA could assume an extensive secondary
structure that contains three stem-loop structures (Fig. 4A).
Deletion to position 153 from the 39 end of the TAR structure
was predicted to have no effects on the formation of the first
stem-loop structure and has no effects on transactivation (Table 2). To further test whether the first stem-loop secondary
structure is required for transactivation by JDV Tat, a set of
JDV LTR mutants, each of which differed from the deletion
clone p3D153 by 3 nt, was generated (Fig. 4B). Mutagenesis
of the stem structure in clones pJD153M1, pJD153M2, and
pJD153M4 was predicted to perturb the proposed secondary
structure within the first stem-loop region, whereas for clone
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pJD153M3 it was predicted to have no effects. Our transactivation results supported the prediction. Clone pJD153M3 still
responded to Tat transactivation, even though the levels were
slightly lower than those for the wild-type construct (p3D153)
(Fig. 4B). In contrast, mutants pJD153M1, pJD153M2, and
pJD153M4, which have mutations in the stem structure, lost
their ability to be stimulated by Tat (Fig. 4B). Our results
indicated that JDV Tat-mediated transactivation was quite
sensitive to changes in RNA secondary structure in the stem
structure of the first stem-loop but was relatively unaffected by
sequence substitutions in the loop region.
Activation of the JDV LTR by BIV Tat and HIV Tat. Given
the similarities of JDV Tat and the JDV TARs with those of
BIV and other primate lentiviruses, we determined if BIV and
HIV Tat could stimulate the JDV LTR. The presence of BIV

FIG. 4. (A) The predicted secondary structure of the putative JDV TAR
region. RNA folding was performed by the RNAFOLD program in the GCG
Wisconsin package. The entire R region of the JDV LTR was included in the
analysis. The free energy for the folded structure is 244.8 kJ/mol. (B) Effects of
site-directed mutagenesis within the first stem-loop structure of JDV TAR on tat
transactivation. Based on the deletion clone p3D153, we constructed a set of
mutation constructs, each of which bears three nucleotide substitutions. The
mutated nucleotides are boldfaced, and their corresponding positions in the
stem-loop structure are shown. In each experiment, 0.5 mg of the wild-type
plasmid (p3D153) or 0.5 mg of each mutant plasmid was cotransfected into CV-1
cells with the JDV tat plasmid. At 48 h posttransfection, cells were lysed and the
lysates were subjected to a CAT ELISA as described in Materials and Methods.
The average fold activation, calculated as described in the legend to Fig. 2 and
derived from three independent experiments, is presented for each plasmid.

tat stimulated JDV LTR expression in both CV-1 and FBL
cells (Fig. 5A). The transactivation levels seemed to be much
lower than those observed with JDV tat (Fig. 2). As observed
with pRSV-JTAT, the levels of transactivation by BIV Tat
seemed to be lower in FBL cells than in CV-1 cells, probably
due to the higher basal level of JDV LTR expression in bovine
cells.
Previous studies with HIV Tat and the BIV LTR have shown
that HIV Tat can stimulate BIV expression, but only a two- to
threefold increase in transactivation was observed in FBL cells
(27). When different concentrations of HIV tat were cotransfected with JDV LTR into FBL cells (Fig. 5B), a maximum of
about twofold transactivation was observed. Interestingly, no

TABLE 2. Effects of JDV LTR deletions on basal expression and transactivation by JDV Tat
JDV LTR expression in:
Promoter plasmida

CV-1 cells
Basal

pJDV-LTR
pJDV-U3R
p3D185
p3D153
p3D121
p5D2196
p5D281
p5D268
p5D250
pJD-81153
pJD-68153

b

650 6 187
626 6 125
836 6 276
676 6 126
2,780 6 607
3,180 6 413
930 6 185
650 6 256
180 6 98
320 6 55
500 6 101

FBL cells
b

c

With JDV Tat

Fold activation

Basal

With JDV-Tat

Fold activation

12,500 6 410
14,460 6 2,579
27,560 6 1,001
21,440 6 4,667
5,060 6 364
48,000 6 17,224
14,700 6 817
20,800 6 1,258
220 6 106
6,120 6 113
12,020 6 947

19.3
23.1
28.3
31.7
1.8
15.1
15.8
32.1
1.2
19.2
24.1

2,120 6 960
1,800 6 617
3,080 6 556
1,994 6 113
7,260 6 1,735
8,280 6 1,887
920 6 54
1,060 6 202
140 6 15
580 6 253
1,130 6 204

17,320 6 820
22,680 6 1,776
17,960 6 5,940
11,780 6 4,861
4,640 6 3,666
40,900 6 10,252
8,520 6 3,488
11,380 6 2,920
180 6 21
6,840 6 1,548
11,740 6 3,408

8.2
12.6
5.8
5.9
0.6
5.1
9.3
10.8
1.2
11.8
10.4

a
CV-1 cells were transfected with 1 mg of each promoter construct and 1 mg of pRSV-JTAT. FBL cells were transfected with 0.5 mg of promoter plasmid and 1 mg
of pRSV-JTAT. The total amount of DNA used for each experiment was kept constant by adjusting with pUC19 plasmid DNA.
b
Expressed as picograms of CAT protein per milligram of total cellular protein. The relative CAT enzyme concentration was determined by extrapolation from the
CAT ELISA, and the absorbance was converted to the amount of CAT enzyme per milligram of total cellular protein by using the CAT standard curve.
c
Calculated by dividing the CAT enzyme concentration in the presence of pRSV-JTAT by the concentration in the absence of pRSV-JTAT.
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FIG. 5. (A) Transactivation of the JDV LTR by BIV Tat in CV-1 and FBL cells. The pJDV-U3R plasmid (1 mg of pJDV-U3R for CV-1 cells and 0.5 mg for FBL
cells) and varying amounts of the BIV tat plasmid (0, 0.25, 0.5, 1.0, and 2.5 mg) were cotransfected into cells by using Lipofectamine as described in Materials and
Methods. (B) Effects of HIV Tat on JDV LTR expression in CV-1 and FBL cells. The pJDV-U3R plasmid (1 mg for CV-1 cells and 0.5 mg for FBL cells) and varying
amounts of the HIV tat plasmid (0, 0.25, 0.5, 1.0, and 2.5 mg) were transfected by using Lipofectamine, and the CAT protein concentration were determined. The fold
activation is shown above each bar.

activation was observed with the largest amount of HIV tat
used. In contrast to FBL cells, no transactivation of the JDV
LTR by HIV tat was observed in CV-1 cells, suggesting that
HIV Tat cannot activate JDV LTR effectively and that cellular
factors may also play a role in the expression and transactivation of the JDV LTR.
Transactivation of BIV and HIV LTRs by JDV Tat. The JDV
Tat protein not only has sequence homology with BIV Tat but
is also structurally quite homologous to the HIV Tat protein,
containing the cysteine, core, and basic functional domains
(24). Therefore, we were interested in determining whether
JDV Tat would stimulate the BIV and HIV LTRs. pRSVJTAT was cotransfected with the BIV and HIV promoters, and
the expression levels were determined. Cotransfection of
pRSV-JTAT and pBIV-LTR-CAT into either CV-1 cells (Fig.
6A) or FBL cells (Fig. 6B) showed very strong transactivation
of the BIV LTR by JDV Tat. JDV Tat was at least as active as
BIV Tat in stimulating BIV LTR expression. It activated the
BIV LTR in CV-1 cells about 29-fold when 0.5 mg of the
plasmid DNA was added. In contrast, similar amounts of BIV
Tat activated the BIV LTR only about 24-fold. Similar patterns
of transactivation were observed in FBL cells. JDV Tat trans-

activated the BIV LTR about 13-fold, while BIV Tat activated
the BIV LTR about 9-fold.
Since it has been demonstrated previously that BIV Tat can
transactivate the HIV LTR (27), and given the similarity between BIV and JDV Tat, JDV Tat was tested for its ability to
activate the HIV LTR. Either JDV tat (pRSV-JTAT) or HIV
tat (pRSV-HTAT) DNA was cotransfected with pHIV-LTRCAT into CV-1 cells at varying concentrations, and the levels
of CAT expression were measured (Fig. 7). The presence of
JDV tat transactivated HIV LTR expression very strongly. The
presence of 1 mg of JDV tat plasmid stimulated HIV expression about 69-fold; a similar amount of HIV tat plasmid stimulated HIV LTR expression about 49-fold. These results suggest that JDV Tat is a potent transactivator for the HIV LTR
and is as active as HIV Tat itself.
JDV Tat can transactivate several other retrovirus LTRs.
Since JDV Tat possesses potent transactivating functions on
heterologous BIV and HIV-1 promoters, it may be a ubiquitous transactivator that can act in a TAR-dependent or TARindependent manner. To test this possibility, JDV Tat was
tested for its activity on several other lentivirus and nonlentivirus retrovirus promoters, such as the HIV-2, simian immu-

FIG. 6. Comparison of the effects of JDV Tat and BIV Tat on BIV LTR expression in either CV-1 (A) or FBL (B) cells. Cells were transfected with 0.5 mg of
pBIV-LTR-CAT and varying amounts of the JDV tat plasmid (0, 0.25, 0.5, 1.0, and 2.5 mg) by using Lipofectamine. The fold transactivation is shown above each bar.

664

CHEN ET AL.

J. VIROL.

FIG. 7. Comparison of the effects of JDV Tat and HIV Tat on HIV LTR
expression. CV-1 cells were transfected with 0.1 mg of pHIV-LTR-CAT and
varying amounts of the JDV or HIV tat plasmid (0, 0.25, 0.5, 1.0, and 2.5 mg) by
using Lipofectamine. The fold transactivation is shown above each bar.

nodeficiency virus (SIV), human T-lymphotropic virus type 1
(HTLV-1), and RSV promoters (Table 3). These promoter
CAT constructs were cotransfected with JDV tat (pRSVJTAT) into either CV-1 or FBL cells, and the transactivation
levels were determined. As expected, JDV Tat activated both
HIV-2 and SIV lentivirus promoters. The levels of activation
were comparable to that observed with the JDV LTR, ranging
from about 17- to 22-fold in CV-1 cells and from about 5- to
9-fold in FBL cells. The lower activation levels observed in
FBL cells were probably due to higher basal expression levels
of these promoters in FBL cells. Interestingly, JDV Tat activated the two nonlentivirus promoters HTLV-1 and RSV.
Even though the levels were much lower with these promoters,
they were significant and consistent. The HTLV-1 promoter
was transactivated by JDV Tat about threefold in CV-1 cells
and twofold in FBL cells; the RSV promoter was activated
about five- and threefold in CV-1 and FBL cells, respectively.
DISCUSSION
Our study is the first to demonstrate that JDV contains a
functional tat gene and that exon 1 alone can transactivate the
JDV LTR-directed gene expression to high levels. JDV Tat not
only transactivated every lentivirus LTR tested but also weakly
activated other, nonlentivirus promoters, probably via a TARindependent mechanism. This suggested that JDV Tat is a
potent and ubiquitous transactivator. This strong transactivation function of JDV Tat may be responsible for the ability of
the virus to replicate to high titers in infected animals. Virus
titers of 108 50% infective doses per ml in blood and plasma of
infected animals have been reported (35, 40). The ability of
JDV Tat to transactivate BIV, HIV, and other lentivirus promoters suggests that it may involve similar mechanisms of
transactivation (8, 11, 12, 14, 15, 17, 28).
Alignment of JDV, BIV, HIV-1, and HIV-2 Tat proteins
showed that JDV Tat has conserved cysteine-rich and core
transactivation regions, like BIV or HIV (Fig. 8). This may
explain why JDV Tat can transactivate BIV, HIV, and other
lentivirus LTRs. The basic region and the amino terminus have
high homology with BIV Tat but not with HIV Tat. The basic
region is responsible for the binding of Tat to TAR. This
suggests that JDV Tat may have a TAR recognition domain
similar to that of BIV Tat and not to that of HIV Tat. Differences in TAR recognition domains may explain why BIV Tat
can transactivate the JDV LTR and HIV Tat cannot. This

speculation is further supported by previous studies demonstrating that BIV Tat can bind to its TAR site with high affinity
and specificity. Unlike HIV Tat, BIV Tat does not appear to
use cellular proteins to stabilize RNA binding in vivo (11). It
turns out that the BIV TAR recognition domain simultaneously recognizes the bulge and stem regions of BIV TAR,
which adopts an unusual structure, whereas HIV Tat proteins
use a single arginine residue within a short region of basic
amino acids to recognize a bulge region in TAR (11). Our
results suggest that JDV Tat may involve a similar BIV-like
TAR recognition domain. The JDV and BIV Tat proteins are
much closer phylogenetically and may have evolved to use
similar mechanisms to recognize their RNA targets.
Previous studies on transactivation have focused mainly on
the HIV tat gene. Cellular proteins termed cyclin T and cyclindependent kinase 9 (CDK9) have recently been found to be
involved in transcription activation of the HIV-1 LTR by Tat
(41, 43). HIV Tat is predicted to interact directly with cyclin T,
which, in turn, specifically binds to CDK9 to form a Tat-cyclin
T-CDK9 complex (13, 39). Tat appears to bind the cyclin-T
complex and to recruit the complex to the HIV-1 promoter, a
process that requires the binding of Tat to the TAR bulge and
of cyclin T to the TAR loop. The cyclin-T-associated CDK9
can then phosphorylate the C-terminal domain of RNA polymerase II, leading to a transition from nonpossessive to possessive transcription (13). It is possible that in transactivation
of the JDV LTR, JDV Tat adopts a mechanism similar to that
of HIV. Several lines of evidence suggest that this might be the
case. First, sequence analysis indicated that JDV Tat had some
sequence homology with HIV Tat and contained similar highly
conserved domains. Our data also showed that JDV Tat could
strongly activate the HIV LTR, although HIV Tat cannot
activate the JDV LTR. Second, the RNA sequence downstream of the transcription start site in JDV could assume
stem-loop structures similar to those of the HIV TAR. Our
deletion mapping and mutagenesis data presented in this study
showed that the first TAR stem-loop structure was critical for
transactivation by JDV Tat. Transactivation of the pJD185
and pJD153 deletion clones demonstrated wild-type levels of
Tat transactivation, suggesting that the second and third stemloop structures between 135 and 1108 may be dispensable for
transactivation. However, we cannot rule out the possibility
that the distal stem-loop structures play a role in the regulation
of JDV LTR transcriptional activation in vivo. Detailed analysis of stem-loops 2 and 3 of the JDV LTR is required in order
to further elucidate their roles in transactivation. The roles of
the additional stem-loop structures in transactivation have not
been well characterized, although they are also present in
other lentivirus LTRs, such as those of BIV, HIV-2, and SIV
(3, 7, 16, 38). Previous reports of deletion analysis of the HIV-2

TABLE 3. Effects of JDV Tat on different viral promoters in CV-1
and FBL cells
Promoter constructa

pJDV-U3R
pHIV2-LTR-CAT
pSIV-LTR-CAT
pHTLV-LTR-CAT
pRSV-LTR-CAT

Fold activationb in:
CV-1 cells

FBL cells

22.0 6 2.3
16.7 6 4.9
20.5 6 7.8
3.2 6 1.1
5.1 6 1.2

8.0 6 2.7
9.4 6 0.6
5.4 6 0.7
1.8 6 0.4
2.9 6 0.3

a
For each transfection, 0.5 mg of promoter plasmid and 1 mg of JDV tat
plasmid were used.
b
Fold activation was calculated as described in the legend to Fig. 2.

VOL. 73, 1999

JEMBRANA DISEASE VIRUS tat GENE

665

FIG. 8. Alignment of amino acid sequences of JDV, BIV, HIV-2, and HIV-1 Tat exon 1. Peptide sequences were aligned with the GCG Pileup program. The
putative N-terminal (N-TERM), cysteine-rich (CYS-RICH), core region, basic, and C-terminal (C-TERM) domains of Tat are underlined and labeled (24). Asterisks
mark amino acids that are conserved in JDV and other Tat sequences.

LTR have shown that in addition to the first stem-loop, the
second stem-loop was also needed for optimal activity (3).
Elimination of the second stem-loop resulted in a two- to
threefold reduction in transactivation. In contrast, deletion of
the third stem-loop had no effect on transactivation (16).
Like BIV and HIV, JDV Tat is encoded by two exons. This
study focused only on exon 1 and indicated that the protein
encoded by exon 1 is a strong transactivator analogous to HIV
Tat. However, at this time we do not know what role exon 2
may play and whether it is dispensable for transactivation by
JDV Tat in vivo. Since no infectious JDV cDNA clone is
available, it is difficult at present to elucidate the function of
JDV tat exon 2. For HIV, mutagenesis studies based on transfection assays indicated that the second coding exon is dispensable for transactivation (22, 26, 30, 32, 34). However, other
studies have also shown that HIV-1 tat exon 2 plays a role in
the optimal activation of integrated LTRs but not of unintegrated LTRs (23).
Besides the virus-encoded Tat, many cellular factors were
reported to be involved in basal promoter expression and
transactivation. For the JDV LTR, a deletion of the upstream
sequence from nt 2236 to nt 2196 seemed to increase basal
promoter activity about fivefold in CV-1 cells and fourfold in
FBL cells, suggesting the possibility that a negative regulatory
element exists, located between nt 2196 and 2236. Negative
elements have indeed been found or suggested in a number of
other lentiviruses, including EIAV, BIV, feline immunodeficiency virus, and HIV-1 (7, 15, 31). Previous studies on the
HIV LTR indicate that the U3 region plays a very important
role in TAR-dependent transactivation (4). In the JDV LTR,
several enhancer motifs, such as NF-kB, the core enhancer
element, Sp-1, and AP-4, were identified by sequence analysis
(9). Our set of U3 deletion clones containing NF-kB, SP-1,
core enhancer, and AP-4 deletions have different basal promoter activities, but their abilities to be transactivated by Tat
were not affected. However, even though the deletion clone
pJD-50, in which the last predicted cellular binding site (AP-4)
was deleted, was still competent for basal expression, it was no
longer transactivated by Tat. This suggests that besides TAR,
additional elements, such as AP-4, may be required for efficient transactivation by Tat. Additional studies are required in
order to elucidate the exact function of various elements in the
U3 region that may participate in Tat transactivation.
We conclude that JDV, a newly characterized member of
the lentivirus family, carries a potent tat gene and uses the
common transactivation mechanisms adopted by other lentivi-

ruses, including BIV and HIV. The ability of JDV Tat to
transactivate its promoter expression strongly may play an important role in its pathogenesis. The disease course during
JDV infection must involve a complex interaction between the
virus and the host immune response, as well as an interplay
between viral and cellular regulatory factors (18, 29, 34, 37).
Therefore, whether a potent and ubiquitous transactivator like
JDV Tat plays a role in viral pathogenesis and acute disease
manifestation requires further investigation. Further understanding of the regulatory mechanisms of JDV and BIV may
provide useful insights into the pathogenesis of lentiviruses.
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